I’m Rebecca, founder of EVIDOSE®.

I studied Nutrition and Food Science at the University of Reading before completing a Master’s degree in Digital Health (MSc). 

Health challenges within my family prompted me to look more closely at the gut microbiome and the evidence behind live bacteria supplements. I became particularly interested in whether the strains and doses used in products actually reflected those studied in human clinical research.

I found that products varied considerably. Some identified only the bacterial species rather than the specific strain, while others contained strains or doses with relatively limited supporting human research.

This became the basis for EVIDOSE®.

When developing Live Biotic Daily+, I reviewed the published clinical research and existing market and worked with specialists in the field to help shape the formulation. We chose four specific strains with substantial human research behind them:

• Lactobacillus rhamnosus GG
• Lactobacillus acidophilus NCFM
• Bifidobacterium lactis HN019
• Bifidobacterium lactis DSM 15954

Each is included at a dose that has been used in human clinical studies. The formula was also developed with sensitive digestion in mind, with no added inulin or FOS, and includes vitamin D3 to support the normal function of the immune system.

Live Biotic Daily+ launched in February 2026, and I’m proud to introduce a probiotic designed to reflect what the evidence actually supports.

I look forward to you discovering Live Biotic Daily+ for yourself.

Best wishes,

Rebecca